Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

APPOINTMENTS: Apellis, Araim, Ascendis, Chronos, Intrexon and Proteostasis

Executive Summary

Chrono Therapeutics Inc. has hired two ex-Shire PLC executives to lead clinical development for the recently acquired pipeline programs it picked up from the Irish pharma company. Meanwhile, Apellis Pharmaceuticals Inc., Ascendis Pharma A/S, Intrexon Corporation and Proteostasis Therapeutics Inc. have made senior appointments and Araim Pharmaceuticals has named a new chair for its board of directors.

You may also be interested in...



Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Coronavirus Update: Pfizer, BioNTech Hit Ground Running On Vaccine EUA

US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.

Executives On The Move: New CEOs Named At Gossamer Bio, Liminal BioSciences

Board directors appointed at Athersys, Trillium Therapeutics and Viatris

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel